Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | AML: options after venetoclax-based regimen failure

Andrius Žučenka • 10 Jun 2022
EHA 2022
Acute Myeloid Leukemia Leukemia Venetoclax

Andrius Žučenka, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, outlines the options for acute myeloid leukemia (AML) patients that fail venetoclax-based regimens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Andrius Žučenka

2:18
VEN-AZA versus intensive chemotherapy as bridging therapy in patients with MDS
Andrius Žučenka • 8 Dec 2023
3:52
Maintenance therapy with revumenib following alloSCT in KMT2Ar and NPM1-mutated acute leukemias
Andrius Žučenka • 8 Dec 2023
2:27
Challenges with managing the high rates of infections seen in patients with AML
Andrius Žučenka • 8 Dec 2023
2:12
Approaching patients with FLT3-mutated AML who are ineligible for high-intensity chemotherapy
Andrius Žučenka • 8 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals